{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:46:53Z","timestamp":1788281213961,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nxera Pharma Japan Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04240-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:12:27Z","timestamp":1774937547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and effectiveness of clazosentan in patients after aneurysmal subarachnoid haemorrhage: a second interim report of a post-marketing surveillance in Japan"],"prefix":"10.1007","volume":"49","author":[{"given":"Hiroyuki","family":"Sakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Togo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"4240_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40779-024-00551-6","volume":"11","author":"B Lv","year":"2024","unstructured":"Lv B, Lan JX, Si YF et al (2024) Epidemiological trends of subarachnoid hemorrhage at global, regional, and national level: a trend analysis study from 1990 to 2021. Mil Med Res 11:46. https:\/\/doi.org\/10.1186\/s40779-024-00551-6","journal-title":"Mil Med Res"},{"key":"4240_CR2","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1161\/strokeaha.119.025997","volume":"51","author":"M Maher","year":"2020","unstructured":"Maher M, Schweizer TA, Macdonald RL (2020) Treatment of spontaneous subarachnoid hemorrhage: guidelines and gaps. Stroke 51:1326\u20131332. https:\/\/doi.org\/10.1161\/strokeaha.119.025997","journal-title":"Stroke"},{"key":"4240_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","volume":"76","author":"N Etminan","year":"2019","unstructured":"Etminan N, Chang HS, Hackenberg K et al (2019) Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol 76:588\u2013597. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0006","journal-title":"JAMA Neurol"},{"key":"4240_CR4","doi-asserted-by":"publisher","unstructured":"Bracard S, Schmitt E (2008) Vasospasm and delayed consequences. Interv Neuroradiol 14 Suppl 1: 17\u201322. https:\/\/doi.org\/10.1177\/15910199080140s105","DOI":"10.1177\/15910199080140s105"},{"key":"4240_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4103\/ajns.AJNS_15_19","volume":"14","author":"VN Yamaki","year":"2019","unstructured":"Yamaki VN, Cavalcanti DD, Figueiredo EG (2019) Delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. Asian J Neurosurg 14:641\u2013647. https:\/\/doi.org\/10.4103\/ajns.AJNS_15_19","journal-title":"Asian J Neurosurg"},{"key":"4240_CR6","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.3892\/mmr.2018.9513","volume":"18","author":"YW Cheng","year":"2018","unstructured":"Cheng YW, Li WJ, Dou XJ et al (2018) Role of endothelin\u20131 and its receptors in cerebral vasospasm following subarachnoid hemorrhage. Mol Med Rep 18:5229\u20135236. https:\/\/doi.org\/10.3892\/mmr.2018.9513","journal-title":"Mol Med Rep"},{"key":"4240_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","volume":"68","author":"AP Davenport","year":"2016","unstructured":"Davenport AP, Hyndman KA, Dhaun N et al (2016) Endothelin Pharmacol Rev 68:357\u2013418. https:\/\/doi.org\/10.1124\/pr.115.011833","journal-title":"Endothelin Pharmacol Rev"},{"key":"4240_CR8","doi-asserted-by":"publisher","first-page":"628956","DOI":"10.3389\/fphar.2020.628956","volume":"11","author":"PE Juif","year":"2021","unstructured":"Juif PE, Dingemanse J, Ufer M (2021) Clinical pharmacology of clazosentan, a selective endothelin a receptor antagonist for the prevention and treatment of aSAH-related cerebral vasospasm. Front Pharmacol 11:628956. https:\/\/doi.org\/10.3389\/fphar.2020.628956","journal-title":"Front Pharmacol"},{"key":"4240_CR9","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/strokeaha.108.519942","volume":"39","author":"RL Macdonald","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S et al (2008) Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 39:3015\u20133021. https:\/\/doi.org\/10.1161\/strokeaha.108.519942","journal-title":"Stroke"},{"key":"4240_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/s1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E et al (2011) Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618\u2013625. https:\/\/doi.org\/10.1016\/s1474-4422(11)70108-9","journal-title":"Lancet Neurol"},{"key":"4240_CR11","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL Macdonald","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E et al (2012) Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 43:1463\u20131469. https:\/\/doi.org\/10.1161\/STROKEAHA.111.648980","journal-title":"Stroke"},{"key":"4240_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000475824","volume":"44","author":"M Fujimura","year":"2017","unstructured":"Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T (2017) Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients. Cerebrovasc Dis 44:59\u201367. https:\/\/doi.org\/10.1159\/000475824","journal-title":"Cerebrovasc Dis"},{"key":"4240_CR13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3171\/2022.2.Jns212914","volume":"137","author":"H Endo","year":"2022","unstructured":"Endo H, Hagihara Y, Kimura N et al (2022) Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg 137:1707\u20131717. https:\/\/doi.org\/10.3171\/2022.2.Jns212914","journal-title":"J Neurosurg"},{"key":"4240_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3171\/2024.4.JNS232191","volume":"142","author":"SA Mayer","year":"2024","unstructured":"Mayer SA, Bruder N, Citerio G et al (2024) REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg 142:98\u2013109. https:\/\/doi.org\/10.3171\/2024.4.JNS232191","journal-title":"J Neurosurg"},{"key":"4240_CR15","unstructured":"Japan Stroke Society Stroke Guidelines Committee Stroke treatment guidelines 2021 for the treatment of stroke (revised version 2025) [Article in Japanese]. https:\/\/www.jsts.gr.jp\/img\/guideline2021_kaitei2025_kaiteikoumoku.pdf. Accessed 9 Jul 2025"},{"key":"4240_CR16","unstructured":"Report on the Deliberation Results. Pharmaceuticals and Medical Devices Agency (2021) https:\/\/www.pmda.go.jp\/files\/000264059.pdf. Accessed 19 Jun 2025"},{"key":"4240_CR17","first-page":"359","volume":"61","author":"N Fujimoto","year":"2024","unstructured":"Fujimoto N, Takeyama K, Aikawa Y et al (2024) [Safety and efficacy of PIVLAZ\u00ae 150 mg intravenous infusion (generic name: clazosentan sodium) in patients after surgery for subarachnoid hemorrhage due to cerebral aneurysm: interim report of a domestic specific drug use investigation]. Shinryo Shinyaku (Med Cons New-Remed) 61:359\u2013377. https:\/\/www.shinryo-to-shinyaku.com\/db\/pdf\/sin_0061_06_0359.pdf","journal-title":"Shinryo Shinyaku (Med Cons New-Remed)"},{"key":"4240_CR18","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.3390\/jcm14103423","volume":"14","author":"H Kondo","year":"2025","unstructured":"Kondo H, Ishii D, Kuwabara M et al (2025) Multicenter validation of a unified evidence-based treatment protocol focusing on clazosentan for managing subarachnoid hemorrhage. J Clin Med 14:3423. https:\/\/doi.org\/10.3390\/jcm14103423","journal-title":"J Clin Med"},{"key":"4240_CR19","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108296","volume":"34","author":"R Ando-Matsuoka","year":"2025","unstructured":"Ando-Matsuoka R, Kawada K, Niimura T et al (2025) Risk factors for clazosentan-induced fluid retention in subarachnoid hemorrhage from the Japanese adverse event database. J Stroke Cerebrovasc Dis 34:108296. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2025.108296","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"4240_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10143-023-02104-2","volume":"46","author":"S Muraoka","year":"2023","unstructured":"Muraoka S, Asai T, Fukui T et al (2023) Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. Neurosurg Rev 46:195. https:\/\/doi.org\/10.1007\/s10143-023-02104-2","journal-title":"Neurosurg Rev"},{"key":"4240_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1227\/NEU.0b013e31821d2b49","volume":"69","author":"D Wachter","year":"2011","unstructured":"Wachter D, Hans F, Kreitschmann-Andermahr I, Rohde V (2011) Lower incidence of transcranial doppler and symptomatic vasospasm after aneurysmal subarachnoid hemorrhage and aneurysm clipping in the elderly patient? Neurosurgery 69:261\u20136. https:\/\/doi.org\/10.1227\/NEU.0b013e31821d2b49","journal-title":"Neurosurgery"},{"key":"4240_CR22","doi-asserted-by":"publisher","first-page":"e1017","DOI":"10.1016\/j.wneu.2024.05.036","volume":"187","author":"A Becerril-Gaitan","year":"2024","unstructured":"Becerril-Gaitan A, Nguyen T, Liu C et al (2024) The effect of age on cerebral vasospasm and delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. World Neurosurg 187:e1017\u2013e1024. https:\/\/doi.org\/10.1016\/j.wneu.2024.05.036","journal-title":"World Neurosurg"},{"key":"4240_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3171\/2020.3.JNS193400","volume":"134","author":"EF Aldrich","year":"2021","unstructured":"Aldrich EF, Higashida R, Hmissi A et al (2021) Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 134:1553\u20131561. https:\/\/doi.org\/10.3171\/2020.3.JNS193400","journal-title":"J Neurosurg"},{"key":"4240_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1017\/cjn.2015.288","volume":"43","author":"JM Findlay","year":"2016","unstructured":"Findlay JM, Nisar J, Darsaut T (2016) Cerebral vasospasm: a review. Can J Neurol Sci 43:15\u201332. https:\/\/doi.org\/10.1017\/cjn.2015.288","journal-title":"Can J Neurol Sci"},{"key":"4240_CR25","doi-asserted-by":"publisher","unstructured":"Ogawa S, Koizumi S, Umekawa M et al (2025) Quantitative evaluation of the vasodilatory effect of clazosentan in preventing cerebral vasospasm after subarachnoid hemorrhage. Interv Neuroradiol 15910199251362730. https:\/\/doi.org\/10.1177\/15910199251362730","DOI":"10.1177\/15910199251362730"},{"key":"4240_CR26","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1161\/strokeaha.119.025682","volume":"50","author":"SA Mayer","year":"2019","unstructured":"Mayer SA, Aldrich EF, Bruder N et al (2019) Thick and diffuse subarachnoid blood as a treatment effect modifier of clazosentan after subarachnoid hemorrhage. Stroke 50:2738\u20132744. https:\/\/doi.org\/10.1161\/strokeaha.119.025682","journal-title":"Stroke"},{"key":"4240_CR27","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S et al (2023) 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke 54:e314\u2013e370. https:\/\/doi.org\/10.1161\/STR.0000000000000436","journal-title":"Stroke"},{"key":"4240_CR28","doi-asserted-by":"publisher","first-page":"982498","DOI":"10.3389\/fneur.2022.982498","volume":"13","author":"G Hao","year":"2022","unstructured":"Hao G, Chu G, Pan P et al (2022) Clinical effectiveness of nimodipine for the prevention of poor outcome after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Front Neurol 13:982498. https:\/\/doi.org\/10.3389\/fneur.2022.982498","journal-title":"Front Neurol"},{"key":"4240_CR29","doi-asserted-by":"publisher","unstructured":"Dorhout Mees SM, Rinkel GJ, Feigin VL et al (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007:CD000277. https:\/\/doi.org\/10.1002\/14651858.CD000277.pub3","DOI":"10.1002\/14651858.CD000277.pub3"},{"key":"4240_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3340\/jkns.2024.0195","volume":"68","author":"SH Lee","year":"2025","unstructured":"Lee SH, Choi KS, Togo O, Park IS (2025) Comparison of clazosentan and nimodipine on vasospasm and vasospasm-related outcomes after aneurysmal subarachnoid hemorrhage: a post-hoc propensity score-matched analysis of six randomized clinical trials. J Korean Neurosurg Soc 68:392\u2013404. https:\/\/doi.org\/10.3340\/jkns.2024.0195","journal-title":"J Korean Neurosurg Soc"},{"key":"4240_CR31","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3390\/ijms25052593","volume":"25","author":"M Sohn","year":"2024","unstructured":"Sohn M, Lim S (2024) The role of cilostazol, a phosphodiesterase-3 inhibitor, in the development of atherosclerosis and vascular biology: a review with meta-analysis. Int J Mol Sci 25:2593. https:\/\/doi.org\/10.3390\/ijms25052593","journal-title":"Int J Mol Sci"},{"key":"4240_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000445509","volume":"42","author":"N Matsuda","year":"2016","unstructured":"Matsuda N, Naraoka M, Ohkuma H et al (2016) Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. Cerebrovasc Dis 42:97\u2013105. https:\/\/doi.org\/10.1159\/000445509","journal-title":"Cerebrovasc Dis"},{"key":"4240_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3171\/2012.9.Jns12492","volume":"118","author":"N Senbokuya","year":"2013","unstructured":"Senbokuya N, Kinouchi H, Kanemaru K et al (2013) Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg 118:121\u2013130. https:\/\/doi.org\/10.3171\/2012.9.Jns12492","journal-title":"J Neurosurg"},{"key":"4240_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s13760-023-02207-z","volume":"123","author":"J Wu","year":"2023","unstructured":"Wu J, Gao W, Zhang H (2023) Development of acute lung injury or acute respiratory distress syndrome after subarachnoid hemorrhage, predictive factors, and impact on prognosis. Acta Neurol Belg 123:1331\u20131337. https:\/\/doi.org\/10.1007\/s13760-023-02207-z","journal-title":"Acta Neurol Belg"},{"key":"4240_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.hest.2024.01.004","volume":"5","author":"T Kimura","year":"2024","unstructured":"Kimura T, Suzuki K, Sato H et al (2024) Initial results of clazosentan with multiple-drug management for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Brain Hemorrhages 5:79\u201384. https:\/\/doi.org\/10.1016\/j.hest.2024.01.004","journal-title":"Brain Hemorrhages"},{"key":"4240_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10143-025-03646-3","volume":"48","author":"T Sugiyama","year":"2025","unstructured":"Sugiyama T, Hokari M, Shimbo D et al (2025) Clinical factors associated with delayed ischemic and non-ischemic adverse events in clazosentan therapy after aneurysmal subarachnoid hemorrhage: early insights from a multicenter prospective registry. Neurosurg Rev 48:482. https:\/\/doi.org\/10.1007\/s10143-025-03646-3","journal-title":"Neurosurg Rev"},{"key":"4240_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.hest.2025.04.001","volume":"6","author":"H Suzuki","year":"2025","unstructured":"Suzuki H, Kawakita F, Aoki K, Hakozaki K (2025) Clazosentan for aneurysmal subarachnoid hemorrhage: update from Japan. Brain Hemorrhages 6:261\u2013264. https:\/\/doi.org\/10.1016\/j.hest.2025.04.001","journal-title":"Brain Hemorrhages"},{"key":"4240_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10143-024-02345-9","volume":"47","author":"T Mochizuki","year":"2024","unstructured":"Mochizuki T, Ryu B, Shima S et al (2024) Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan. Neurosurg Rev 47:113. https:\/\/doi.org\/10.1007\/s10143-024-02345-9","journal-title":"Neurosurg Rev"},{"key":"4240_CR39","doi-asserted-by":"publisher","first-page":"1413632","DOI":"10.3389\/fneur.2024.1413632","volume":"15","author":"H Sakata","year":"2024","unstructured":"Sakata H, Kanoke A, Uchida H et al (2024) Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol 15:1413632. https:\/\/doi.org\/10.3389\/fneur.2024.1413632","journal-title":"Front Neurol"},{"key":"4240_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2176\/jns-nmc.2024-0204","volume":"65","author":"S Kajiwara","year":"2025","unstructured":"Kajiwara S, Kawano T, Hasegawa Y et al (2025) Impact of clazosentan on vasospasm reduction and functional recovery after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 65:29\u201336. https:\/\/doi.org\/10.2176\/jns-nmc.2024-0204","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"4240_CR41","doi-asserted-by":"publisher","first-page":"e79497","DOI":"10.7759\/cureus.79497","volume":"17","author":"E Okumura","year":"2025","unstructured":"Okumura E, Nakaya K, Otsuka K, Jimbo H (2025) Treatment outcomes of clazosentan use during the perioperative period for subarachnoid hemorrhage. Cureus 17:e79497. https:\/\/doi.org\/10.7759\/cureus.79497","journal-title":"Cureus"},{"key":"4240_CR42","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3171\/2025.1.Jns242509","volume":"143","author":"S Muraoka","year":"2025","unstructured":"Muraoka S, Izumi T, Nishida K et al (2025) RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 143:624\u2013633. https:\/\/doi.org\/10.3171\/2025.1.Jns242509","journal-title":"J Neurosurg"},{"key":"4240_CR43","doi-asserted-by":"publisher","first-page":"271678X25139906","DOI":"10.1177\/0271678X251399068","volume":"21","author":"H Sakata","year":"2025","unstructured":"Sakata H, Uchida H, Kanoke A et al (2025) Stratified assessment of clazosentan efficacy following subarachnoid hemorrhage: A multi-center cohort study. J Cereb Blood Flow Metab 21:271678X251399068. https:\/\/doi.org\/10.1177\/0271678X251399068","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04240-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:12:29Z","timestamp":1774937549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4240"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04240-x","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This post-marketing drug use-results surveillance was conducted in accordance with the Declaration of Helsinki and in compliance with the Good Post-marketing Study Practice Ordinance issued by the Japanese Ministry of Health, Labour and Welfare. Under the exemptions provided by this ordinance, institutional review board approval and informed consent are not required in Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Hiroyuki Sakata has received honoraria for lecture fees from Nxera Pharma Japan, Co., Ltd. Yuya Takayama, Yuna Iwasaki, Hiroyuki Uchida, Satoshi Nishimoto, and Osamu Togo are employees of Nxera Pharma Japan Co., Ltd., Tokyo, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}